DCI Partners
VC Fund
Tokyo, Japan
DCI Partners is a venture capital firm specializing in the fields of drug discovery and regenerative medicine.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $135M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries DCI Partners invests in
Stages DCI Partners invests in
Countries DCI Partners invests in
Round sizes
Round size
- Series A
- $6.9M–$21M
- Series B
- $449k–$33M
- Venture - Series Unknown
- $552k–$21M
Investment Focus
Industry
- Biotechnology 12 (63%)
- Medical 7 (37%)
- Health Care 7 (37%)
- Product Research 6 (32%)
- Health Diagnostics 5 (26%)
Stage
- Series B 7 (37%)
- Venture - Series Unknown 6 (32%)
- Series A 3 (16%)
- Series C 1 (5%)
- Funding Round 1 (5%)
Country
- Japan 14 (74%)
- Taiwan 2 (11%)
- United States 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses. | $32.8M / Series B / Jun 30, 2026 | ||
| Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $442.5M / May 28, 2026 | ||
| Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products. | $14.1M / Series B / Nov 11, 2025 | ||
| Apeximmune Therapeutics is pioneering a new generation of therapeutic antibodies and biologics that harness the power of the immune system to deliver curative treatments for cancer and autoimmune disease. | $21.3M / Series A / Mar 31, 2025 | ||
| Rege Nephro is a biotech company that specialized in R&D, production and marketing of renal disease therapeutics. | $15.2M / Series B / Oct 07, 2024 | ||
| Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments. | $1.7M / Series C / Sep 06, 2024 | ||
| AceRNA contributes to regenerative medicine and drug discovery through the discovery of novel miRNA functions. | $6.2M / Series B / May 07, 2024 | ||
| LUCA Science develops innovative treatments intended for mitochondrial and related diseases. | $29.2M / Series B / Jun 06, 2022 | ||
| K Pharma Is the development Of the Treatment Of the Spinal Cord injury | $12.2M / Venture - Series Unknown / May 24, 2022 | ||
| Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders. | Series A / Aug 23, 2021 | ||
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does DCI Partners invest in?
DCI Partners invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Venture - Series Unknown stage. Most of the 19 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DCI Partners's check size?
DCI Partners typically joins rounds of $6.9M–$21M at Series A, $449k–$33M at Series B and $552k–$21M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DCI Partners participates in.
When did DCI Partners last invest?
The most recent investment recorded for DCI Partners closed in Jun 2026. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
